Molecular testing and targeted therapy for non-small cell lung cancer: current status and perspectives
EN Imyanitov, AG Iyevleva, EV Levchenko - Critical reviews in oncology …, 2021 - Elsevier
Molecular testing has become a mandatory component of the non-small cell lung cancer
(NSCLC) management. The detection of EGFR, BRAF and MET mutations as well as the …
(NSCLC) management. The detection of EGFR, BRAF and MET mutations as well as the …
[HTML][HTML] Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a …
G Viscardi, AC Tralongo, F Massari… - European Journal of …, 2022 - Elsevier
Background The early crossing of survival curves in randomised clinical trials (RCTs) with
immune checkpoint blockers suggests an excess of mortality in the first months of treatment …
immune checkpoint blockers suggests an excess of mortality in the first months of treatment …
[HTML][HTML] Regulation of PD-L1 Expression by NF-κB in Cancer
F Antonangeli, A Natalini, MC Garassino… - Frontiers in …, 2020 - frontiersin.org
Immune checkpoints are inhibitory receptor/ligand pairs regulating immunity that are
exploited as key targets of anti-cancer therapy. Although the PD-1/PD-L1 pair is one of the …
exploited as key targets of anti-cancer therapy. Although the PD-1/PD-L1 pair is one of the …
[HTML][HTML] Immunotherapy in treating EGFR-mutant lung cancer: current challenges and new strategies
KKW To, W Fong, WCS Cho - Frontiers in Oncology, 2021 - frontiersin.org
Lung cancer is the leading cause of cancer-related deaths worldwide. Immune checkpoint
inhibitors, including monoclonal antibodies against programmed death-1 (PD-1) and …
inhibitors, including monoclonal antibodies against programmed death-1 (PD-1) and …
Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA
M Tsuboi, W Weder, C Escriu, C Blakely, J He… - Future …, 2021 - Future Medicine
Osimertinib is a third-generation, irreversible oral EGFR-tyrosine kinase inhibitor), that
potently inhibits EGFR-tyrosine kinase inhibitor-sensitizing mutations and T790M resistance …
potently inhibits EGFR-tyrosine kinase inhibitor-sensitizing mutations and T790M resistance …
Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC)
WM Brueckl, JH Ficker, G Zeitler - BMC cancer, 2020 - Springer
Background Immune checkpoint inhibitors (ICI) either alone or in combination with
chemotherapy have expanded our choice of agents for the palliative treatment of non-small …
chemotherapy have expanded our choice of agents for the palliative treatment of non-small …
[HTML][HTML] Downregulation of LncRNA-XIST inhibited development of non-small cell lung cancer by activating miR-335/SOD2/ROS signal pathway mediated pyroptotic …
J Liu, L Yao, M Zhang, J Jiang, M Yang… - Aging (albany NY), 2019 - ncbi.nlm.nih.gov
LncRNA-XIST participated in the regulation of Non-small cell lung cancer (NSCLC)
progression, but the underlying mechanisms are still unclear. This study showed that …
progression, but the underlying mechanisms are still unclear. This study showed that …
Assessment of the expression of the immune checkpoint molecules PD‐1, CTLA4, TIM‐3 and LAG‐3 across different cancers in relation to treatment response, tumor …
L Tu, R Guan, H Yang, Y Zhou, W Hong… - … journal of cancer, 2020 - Wiley Online Library
Immune checkpoint molecules have been identified as crucial regulators of the immune
response, which motivated the emergence of immune checkpoint‐targeting therapeutic …
response, which motivated the emergence of immune checkpoint‐targeting therapeutic …
First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status
F Facchinetti, G Mazzaschi, F Barbieri… - European Journal of …, 2020 - Elsevier
Background Pembrolizumab is the first-line standard of care for advanced non–small cell
lung cancer (NSCLC) with a PD-L1 tumour proportion score (TPS)≥ 50%. Eastern …
lung cancer (NSCLC) with a PD-L1 tumour proportion score (TPS)≥ 50%. Eastern …
Circulating T-cell immunosenescence in patients with advanced non–small cell lung cancer treated with single-agent PD-1/PD-L1 inhibitors or platinum-based …
Abstract Purpose: CD28, CD57, and KLRG1 have been previously identified as markers of T-
cell immunosenescence. The impact of immunosenescence on anti-PD (L)-1 (ICI) or …
cell immunosenescence. The impact of immunosenescence on anti-PD (L)-1 (ICI) or …